Sequential is a global leader in the skin microbiome field, a team of PhD experts in testing products and their effect on human health. An Innovate UK- and Enterprise Singapore-backed company, with labs in Cambridge, New York City and Singapore. Awarded the title "Most Significant" Testing Solution in the Industry - (C&T, 2022). To date, Sequential has amassed over 50,000 human skin microbiome samples and corresponding formulations tested in vivo on the skin. With this vast genomic dataset, Sequential is innovating in inflammatory disease areas, for example – acne, atopic dermatitis and rosacea. They have been previously supported by Innovate UK, Enterprise SG, A*STAR (Genome Institute of Singapore), SOSV, Corundum Systems Biology and other leading organisations.